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New developments in the diagnosis and treatment of pelvic floor disorders have created a
need for a concise synopsis for clinicians. Our aim is to critically review new diagnostic and
treatment innovations rather than to comprehensively review this field.
Defecatory Disorders
It is now widely appreciated that there are 2 principal etiologies for symptoms of
constipation: delayed transit through the colon and impaired evacuation of the rectum.
Impaired rectal evacuation can result from mechanical obstruction (eg, from rectal cancer or
intussusception of the mucosa), but the more commonly encountered causes are inadequate
rectal propulsion owing to a failure to increase intrarectal pressure during evacuation, or
paradoxical contraction or impaired ability to relax the pelvic floor muscles during
defecation. “Disordered defecation” is an umbrella term meant to encompass the last 2
causes of dysfunctional evacuation.1
Etiology and Pathophysiology
Disordered defecation is often viewed as maladaptive learning of sphincter contraction
motivated by avoidance of pain or trauma.2 However, alternative etiologies and
pathophysiologic mechanisms have been suggested, including rectal hyposensitivity,3
perineal laxity manifested by excessive perineal descent,4 and delayed colonic
transit.5,6Rectal hyposensitivity and delayed transit may be consequences rather than causes
of obstructed defecation because they improve after successful biofeedback treatment.6
Clinical Evaluation
Symptoms of excessive straining, anal digitation, and a sense of anal blockage strongly
suggest disordered defecation. Rectal examination findings of high anal canal resting
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pressure, reduced or increased perineal descent, and paradoxical contraction when instructed
to strain to defecate are also suggestive, but lack specificity.
Diagnostic assessment—The Rome criteria for diagnosis of disordered defecation
include symptoms of chronic constipation consistent with the diagnosis of functional
constipation7 plus at least 2 of 3 physiologic signs:1 (1) inadequate intra-abdominal pressure
during straining, (2) incomplete evacuation of the rectum, and/or (3) <20% relaxation of
anal canal pressures or pelvic floor electromyographic (EMG) activity during straining. In
most patients, anorectal manometry and a rectal balloon expulsion test suffice. When these
tests are discrepant or differ from the clinical impression, defecography or pelvic floor
imaging may be useful.
Management—Biofeedback—a learning-based treatment that relies on providing
electronically augmented feedback to help patients learn how to relax or contract muscles at
appropriate times to reduce symptoms—was proposed for the treatment of disordered
defecation soon after the discovery of this type of constipation.8 Until recently, however,
biofeedback was applied haphazardly and with inconsistent results, partly because of 2
widely held beliefs: (1) that disordered defecation and slow transit constipation frequently
overlap with no clear distinction between them,9 and (2) that biofeedback is just as effective
for slow transit constipation as it is for disordered defecation.10 A study by Chiarioni et al6
corrected these misperceptions. This team recruited 52 patients, all of whom had delayed
transit on a Sitzmark test, and then used anorectal manometry and balloon defecation tests to
identify a subgroup of 34 who also had disordered defecation. They treated all these patients
with 5 sessions of biofeedback to teach relaxation of the pelvic floor muscles during
defecation and showed that 71% of patients with dyssynergic defecation achieved adequate
relief of constipation and 76% had ≥3 bowel movements per week after biofeedback
training, compared with 8% of patients with slow transit only. They also showed that transit
times improved and were within the normal range after biofeedback for 65% of patients with
disordered defecation but just 8% of the slow transit only group. Thus, this study showed
that (1) the only constipated patients who are likely to benefit from this type of biofeedback
treatment are those who have disordered defecation as evidenced by failure to evacuate a 50-
mL, water-filled balloon and/or failure to relax pelvic floor muscles when straining to
defecate and (2) the confusion over whether biofeedback also benefits patients with slow
transit constipation is likely due to the fact that disordered defecation may secondarily delay
transit, with normalization after biofeedback to eliminate dyssynergia.
Three new randomized, controlled trials (RCTs) provide compelling evidence that
biofeedback is an effective treatment for disordered defecation in adults. One study
compared biofeedback with a laxative, polyethylene glycol11; a second compared
biofeedback with sham feedback12; and the third compared it with a muscle relaxer,
diazepam.13 Another RCT made the interesting observation that successful muscle
retraining can be accomplished without electronic feedback provided the therapist
substitutes verbal feedback on performance and praise for success based on ongoing digital
rectal examination.14
These 4 RCTs resulted in standardization of the biofeedback training protocol15 and
recognition that the skill and experience of the therapist and the patient’s motivation are
critical factors. Successful protocols have employed 5–6 training sessions lasting 30–60
minutes and spaced 2 weeks apart. Training sessions should include (1) patient education
about the normal physiology of defecation and what the patient is doing wrong; (2) straining
training, which involves showing the patient how to increase intra-abdominal pressure
appropriately; (3) using electronic feedback of pelvic floor EMG or anal canal pressures to
show the patient how to relax pelvic floor muscles when straining; and (4) practice of
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simulated defecation, usually accomplished by having them defecate an air-filled balloon
while the therapist assists by pulling on a catheter attached to the balloon. (5) Some centers
also include sensory training to teach the patient how to recognize weaker sensations of
rectal filling. Although this biofeedback training protocol has been successful in all recent
RCTs in adults, it does not seem to be more effective than laxatives in children,16 possibly
because children lack the sustained attention and motivation that is required for biofeedback
training.
Other Approaches to Treatment
In children, disordered defecation is called functional fecal retention, and treatment
recommendations include dietary changes, use of laxatives, and cognitive and behavioral
interventions to decrease phobia of the toilet.17 When these conservative measures fail,
investigational treatments have included botulinum toxin injection into the puborectalis
muscle, partial division of the puborectalis, and myectomy. Botulinum produced better
short-term outcomes than biofeedback in 1 study,18 and short-term improvements
comparable with partial division of the puborectalis19 or myectomy20 in other studies. An
uncontrolled study21 suggests that botulinum may also improve disordered defecation in
adults. However, improvements with botulinum were short lived, limiting its usefulness for
this chronic disorder. Partial division of the puborectalis and myectomy produced sustained
improvements in constipation, but a few patients developed fecal incontinence after division
of the puborectalis. The authors do not regard myectomy or partial division of the
puborectalis as a viable alternative to behavioral or medical treatment of disordered
defecation because it is believed to be a behavioral disorder2—there is no neurologic or
structural lesion—and surgical treatments for behavioral disorders entail an unacceptable
risk of morbidity. Small uncontrolled studies suggest that sacral nerve stimulation (SNS)
may also improve symptoms in some patients with chronic constipation and disordered
defecation.22
Chronic Proctalgia
Chronic proctalgia is defined by chronic or recurring bouts of rectal pain in which episodes
last ≥20 minutes and in which no structural or inflammatory etiology can be identified.1
When posterior traction on the puborectalis muscle during digital examination produces
tenderness, the more specific diagnosis is levator ani syndrome. This common and
debilitating condition is frustrating to treat.
Diagnostic assessment—The diagnosis of chronic, idiopathic proctalgia is made
primarily by exclusion of other diseases that could explain the symptom of chronic rectal
pain, and the differential is large and poorly standardized. For example, in the recent study
by Chiarioni et al,23 the diagnostic evaluation included digital rectal examination by a
gastroenterologist, colonoscopy, pelvic ultrasound, and surgical consultation in all patients,
plus referral to a gynecologist or urologist when indicated by clinical history or findings.
The principal innovation in diagnostic assessment is that tenderness from palpation of the
levator muscles is an excellent predictor of the likelihood of benefit from biofeedback
(Figure 1).23
Management—Although there is no consensus on the pathophysiology of chronic
proctalgia, the pain is often assumed to be due to tense pelvic floor muscles, and the most
frequently recommended treatments are biofeedback, electrogalvanic stimulation (EGS), and
massage of the puborectalis muscles to relax these muscles. Inconsistent results have been
reported for each of these treatments. In a large RCT comparing these treatments, Chiarioni
et al23 randomized 157 patients with at least weekly rectal pain to 9 sessions of biofeedback,
EGS, or massage. Psychological counseling was included in each treatment arm. Before
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randomization, patients were stratified based on whether they reported tenderness with
traction on the pelvic floor. Among patients with tenderness, 87% reported adequate relief
after biofeedback versus 45% for EGS, and 22% for massage. These differences in
subjective outcomes were confirmed by greater reductions in pain days per month with
biofeedback, and improvements were maintained at 12 months follow-up. However, patients
with no tenderness on digital examination did not benefit from any of these treatments.
This study revealed that the pathophysiology of levator ani syndrome is remarkably similar
to disordered defecation. Inability to relax the pelvic floor muscles during attempted
defecation and/or inability to evacuate a 50-mL, water-filled balloon before treatment
predicted response to biofeedback therapy; moreover, the biofeedback protocol developed
for treatment of disordered defecation was the most effective treatment, and improvement
depended on acquisition during treatment of the ability to relax pelvic floor muscles during
defecation and to evacuate a balloon. Although constipation is not a hallmark of levator ani
syndrome and the patients had stool frequencies within the normal range, stool frequency
nevertheless increased significantly in patients who reported adequate relief of rectal pain
after treatment. Thus, levator ani syndrome and defecatory disorders seem to represent
different symptom manifestations of the same underlying pathophysiology. Possibly other
factors, such as whole gut transit and/or pain sensitivity, determine symptom selection in
patients with pelvic floor dyssynergia. An algorithm for diagnosis and management of
chronic proctalgia based on these new findings is given in Figure 1.
Fecal Incontinence
Epidemiology
Fecal incontinence—recurrent uncontrolled passage of feces but not flatus alone—has a
prevalence of 2.2%– 15.3% in noninstitutionalized adults, and can substantially impair
quality of life.24–28 Risk factors include age, diarrhea, urgency to defecate, and a variety of
medical conditions.28–31
Etiology and Pathophysiology
Diseases that affect bowel habits and/or pelvic floor continence mechanisms can cause fecal
incontinence.29 Iatrogenic anal sphincter injury, radiation proctitis, and rectal evacuation
disorders are common causes in men. Overt obstetric anal sphincter injury can cause
postpartum fecal incontinence. However, among community women, the median age of
onset of fecal incontinence is the 7th decade.26 The contribution of obstetric anal injury,
often evident by imaging only, to delayed onset fecal incontinence is unclear. The
contributions of aging, menopause, and chronic straining to fecal incontinence are
incompletely understood.
There have been 4 significant contributions to our understanding of the pathophysiology of
fecal incontinence in the past 5 years. (1) In addition to sphincter tears or scars, some
women with fecal incontinence have atrophy of the external anal sphincter or puborectalis
identified by magnetic resonance imaging (MRI); in a controlled study 16% of women with
fecal incontinence but only 5% of age-matched controls had puborectalis atrophy, which
was associated with impaired functions in fecal incontinence32 (Supplementary Table 1). (2)
Rectal urgency is now recognized to be an important risk factor for fecal incontinence that is
independent of diarrhea.31 (3) Rectal hypersensitivity, a stiffer rectum, and reduced rectal
capacity, which are frequently associated with the symptom of urgency, are risk factors for
fecal incontinence.32–36 Anal weakness and rectal hyposensitivity were already identified as
risk factors in a subset of patients, especially those with diabetic neuropathy.37 (4) New data
suggest that dyssynergic defecation may result in incomplete rectal emptying and predispose
to fecal incontinence.38
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The history often reveals important clues (eg, an association between postcholecystectomy
diarrhea and fecal incontinence) to the etiology of fecal incontinence, which can guide
therapy.29 Bowel habits are most effectively characterized by pictorial scales.39 Severity and
impact on quality of life can be rated by instruments.26,27,40 A careful digital rectal
examination is very useful for gauging anal resting and squeeze pressures and puborectalis
function. Examination in the seated position may be more accurate for assessing rectal
prolapse, pouch of Douglas hernia, or excessive perineal descent.
Diagnostic Testing
Endoscopy with biopsies if necessary should be considered. A rigorous trial of conservative
measures is justified before diagnostic testing, particularly in older patients, those with mild
symptoms, and those with bowel disturbances. Anal manometry, rectal sensation, and a
rectal balloon expulsion test are useful initial tests, proceeding to anal imaging when anal
pressures are reduced (Figure 2).41,42 Anal sphincter EMG is required infrequently, to
confirm neurogenic injury, particularly a spinal cord or sacral root process. Pudendal nerve
latencies are not accurate for identifying neurogenic injury in fecal incontinence.43
Evacuation proctography is useful to assess perineal descent, pelvic organ prolapse,
rectoceles, defecation, and puborectalis contraction.43 With rapid MRI sequences, MRI can
visualize both anal sphincter anatomy and global pelvic floor motion in real time without
radiation exposure.4,32,44 Anal MRI and endoscopic ultrasound have reminded us that the
puborectalis contributes to fecal continence in the proximal anal canal.45 In contrast with
ultrasound examination, MRI also demonstrates atrophy of the external sphincter and
puborectalis in some women with fecal incontinence.32,46 MRI is comparable to ultrasound
for visualizing internal sphincter abnormalities.47 Although ultrasound is routinely
performed with an endoanal probe, a transperineal probe may also visualize anal sphincter
defects.48
Consideration should be given to referring independently living patients with moderate-to-
severe fecal incontinence to specialist centers for further assessment under the following
circumstances: (1) When symptoms cannot be explained by routine diagnostic tests, for
example, when anal sphincter weakness is mild and/or cannot be attributed to sphincter
disturbances documented by ultrasound. (2) Before considering repair of external sphincter
defects in older women. Because surgical repair is not always successful, careful
consideration of other factors contributing to incontinence, perhaps supplemented by pelvic
MRI to identify external sphincter atrophy may be useful. (4) For patients who have fecal
and urinary incontinence, sacral nerve stimulation (SNS) is an US Food and Drug
Administration (FDA)–approved procedure for urge urinary incontinence; bowel symptoms
may also respond to SNS (see below).
Management
Management is tailored to clinical manifestations and includes treatment of underlying
diseases (Supplementary Table 2). Management of bowel disturbances with simple
approaches (eg, anti-diarrheals taken before social occasions or meals) is critical and often
therapeutic. Loperamide (2–4 mg, 30 minutes before meals, titrated to reduce diarrhea but
avoid constipation, up to 16 mg/d) reduced diarrhea and fecal incontinence and increased
anal tone.49 Diphenoxylate, alosetron (for refractory diarrhea), and cholestyramine
(especially for postcholecystectomy diarrhea) are other options. Regular evacuation
programs, incorporating timed evacuation by digital stimulation and/or bisacodyl/glycerol
suppositories, fiber supplementation, and selective use of oral laxatives as detailed
elsewhere are useful for constipation.50 Per-anal phenylephrine, which is an α1-adrenergic
agonist, increased anal resting pressures but did not improve fecal incontinence.51,52
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Controlled trials reinforce the role of conservative measures (eg, diet and skin care, bowel
medications, urge suppression techniques), and when these measures are ineffective,
biofeedback therapy for fecal incontinence.53 Using a rectal balloon with anal manometry or
a surface electromyography device, patients are taught to contract the external anal sphincter
when they perceive balloon distention; perception may be reinforced by visual tracings of
balloon volume and anal pressure, and the procedure is repeated with progressively smaller
volumes. In an RCT of 171 incontinent patients, effects on symptoms (ie, improved in 55%
and resolved in 5%) and anal pressures were comparable in 4 groups: standard medical/
nursing care (advice only), advice plus verbal instruction on sphincter exercises, hospital-
based computer-assisted sphincter pressure biofeedback, or hospital biofeedback plus use of
a home EMG biofeedback device.54 This improvement was sustained at 1 year after therapy.
In another RCT of 108 patients, 22% responded to conservative therapy for 4 weeks. Among
the remainder, response rates were better in those who received 6 biweekly sessions with
EMG-assisted biofeedback and pelvic floor exercises (77% reported adequate relief and
66% were completely continent) than pelvic floor exercises alone (41% reported adequate
relief and 48% were completely continent).53 A key question is whether instrumented
biofeedback is comparable to teaching pelvic floor exercises by digital examination with
verbal feedback.
Available surgical options include (1) anal sphincteroplasty for women with postpartum
fecal incontinence and anal sphincter defects not responding to conservative management
and (2) for women with truly medically refractory fecal incontinence—a colostomy,
artificial anal sphincter, SNS, or dynamic graciloplasty, the hardware for which is not
approved for use in the United States. The role of sphincteroplasty in older women with
fecal incontinence and anal sphincter defects is limited because short-term symptom
improvement is not sustained; for example, only 21% were continent at 40 months in 1
study.55 Although the intent-to-treat response rates for artificial sphincter and graciloplasty
are 50%–60%, significant morbidity, including infections and device problems sometimes
necessitating reoperation or explanation, are common.56,57
SNS is approved for treating fecal incontinence in Europe and is FDA-approved for treating
urinary but not fecal incontinence in the United States. This is a staged procedure; when
symptoms respond to temporary stimulation for 3 weeks, the device is implanted
subcutaneously. The procedure is technically straightforward, complications are infrequent,
and symptoms improve substantially. In 1 crossover study of 34 patients,58 symptoms
improved by 90% during stimulation versus 76% without stimulation; the order of
stimulation was randomized. In another controlled study, SNS improved symptoms and
quality of life to a greater extent than “optimal medical management” (ie, bulking agents,
pelvic floor exercises, and dietary management); use of anti-diarrheal agents was not
specified.59 A North American multicenter study observed that 120 of 133 patients (90%)
proceeded from test to chronic SNS at 12 months, 83% of subjects (95% CI; 74–90%)
achieved therapeutic success, defined by ≥50% reduction in incontinence episodes.60
Limited data suggest that the SNS is also effective in patients with sphincter defects.61 SNS
is approved for treating fecal incontinence by the National Institute for Clinical Excellence
in the United Kingdom. The discrepancy between symptom improvement and inconclusive
effects on anal pressures, rectal compliance, and rectal sensation is puzzling.62–64 Anal
electrical stimulation is not beneficial and measures to bulk the anal sphincter with silicon
and carbon beads are not ready for prime time.65–67 Anal sphincteric injection of autologous
myoblasts derived from a pectoralis muscle biopsy was well tolerated and improved
symptoms in 10 women with fecal incontinence, but there was no clinically significant
improvement in anal resting and squeeze pressures.68 Attempts to bioengineer sphincteric
rings from human internal anal sphincter smooth muscle cells are in progress.69
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Recent studies strengthen substantially the evidence that biofeedback is the preferred
treatment for disordered defecation and levator ani syndrome, and identify patient
characteristics that predict successful outcomes. Biofeedback does not benefit patients with
constipation due primarily to slow transit, but is effective in patients with either inability to
evacuate a balloon or impaired relaxation of pelvic floor muscles during straining. For
chronic proctalgia, the same 2 signs plus tenderness on palpation of the pelvic floor predict
success. Conservative measures, including careful characterization and management of
bowel disturbances, is key to managing fecal incontinence. A new RCT carried out in
patients who failed conservative management demonstrated that biofeedback provided
additional benefit for fecal incontinence and was superior to pelvic floor exercises.
However, other studies suggest that when patients are taught how to perform pelvic floor
exercises with verbal guidance from a therapist during digital rectal examination, this may
be as effective as biofeedback provided by machines. Limitations of biofeedback are the
paucity of well-trained therapists and limited efficacy in children. RCTs also support the
efficacy of SNS for fecal incontinence, but this is not yet approved for use in the United
States. New diagnostic techniques including pelvic floor MRI have increased our
understanding of the risk factors and pathophysiology of anorectal disorders. Pending
approval by the FDA, sacral nerve stimulation is a new option for patients with fecal
incontinence who have failed conservative therapy.
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Algorithm for the diagnosis and management of chronic proctalgia. Abbreviations: ARM,
anorectal manometry; EGS, electrogalvanic stimulation.
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